Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
1-15 of 435
Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Project Oncology®Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Project Oncology®A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Project Oncology®Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Geoffrey Oxnard, MD
Integrating Molecular Testing into NSCLC Care
Project Oncology®Integrating Molecular Testing into NSCLC Care
Geoffrey Oxnard, MD
Smarter Screening for Non-Small Cell Lung Cancer
Project Oncology®Smarter Screening for Non-Small Cell Lung Cancer
Jobelle Baldonado, MD
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®A New Era of Hope in Non-Small Cell Lung Cancer Care
Geoffrey Oxnard, MD
- advertisement
Improving Adherence and Toxicity Monitoring in NSCLC Care
Project Oncology®Improving Adherence and Toxicity Monitoring in NSCLC Care
Raghava Reddy Induru, MD
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Project Oncology®The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Raghava Reddy Induru, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Project Oncology®Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Laura Alder, MD
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Project Oncology®Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Laura Alder, MD
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Project Oncology®Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Laura Alder, MD
The Importance of Multidisciplinary Coordination in NSCLC Care
Project Oncology®The Importance of Multidisciplinary Coordination in NSCLC Care
Laura Alder, MD
- advertisement
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Project Oncology®Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Christine Bestvina, MD
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Project Oncology®Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Christine Bestvina, MD
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS
Shannon Raber, MS, CPNP, RN
Bridget Archambault, MSN, CPNP
